Moreover, treatment of simBOs with PFE-360, an LRRK2 inhibitor, could relieve the abnormalities, suggesting the potentiality of simBOs serving as PD models and alternative platforms for drug-testing and screening [68]. Here, LRRK2 is linked to Parkinson disease.